ATE187648T1 - Zusammensetzungen enthaltend lipoprotein- associated-coagulation-inhibitor (laci) zur herstellung eines medikaments zur behandlung von akuten oder chronischen enzündungen - Google Patents

Zusammensetzungen enthaltend lipoprotein- associated-coagulation-inhibitor (laci) zur herstellung eines medikaments zur behandlung von akuten oder chronischen enzündungen

Info

Publication number
ATE187648T1
ATE187648T1 AT93910775T AT93910775T ATE187648T1 AT E187648 T1 ATE187648 T1 AT E187648T1 AT 93910775 T AT93910775 T AT 93910775T AT 93910775 T AT93910775 T AT 93910775T AT E187648 T1 ATE187648 T1 AT E187648T1
Authority
AT
Austria
Prior art keywords
laci
treatment
medication
acute
producing
Prior art date
Application number
AT93910775T
Other languages
English (en)
Inventor
Abla A Creasey
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Application granted granted Critical
Publication of ATE187648T1 publication Critical patent/ATE187648T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
AT93910775T 1992-06-01 1993-04-23 Zusammensetzungen enthaltend lipoprotein- associated-coagulation-inhibitor (laci) zur herstellung eines medikaments zur behandlung von akuten oder chronischen enzündungen ATE187648T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89194792A 1992-06-01 1992-06-01
US450593A 1993-01-13 1993-01-13
PCT/US1993/003860 WO1993024143A1 (en) 1992-06-01 1993-04-23 A method for using lipoprotein associated coagulation inhibitor to treat sepsis

Publications (1)

Publication Number Publication Date
ATE187648T1 true ATE187648T1 (de) 2000-01-15

Family

ID=26673093

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93910775T ATE187648T1 (de) 1992-06-01 1993-04-23 Zusammensetzungen enthaltend lipoprotein- associated-coagulation-inhibitor (laci) zur herstellung eines medikaments zur behandlung von akuten oder chronischen enzündungen

Country Status (10)

Country Link
EP (1) EP0643585B1 (de)
JP (3) JP3957740B2 (de)
AT (1) ATE187648T1 (de)
CA (1) CA2136953C (de)
DE (1) DE69327314T2 (de)
DK (1) DK0643585T3 (de)
ES (1) ES2139658T3 (de)
GR (1) GR3032779T3 (de)
PT (1) PT643585E (de)
WO (1) WO1993024143A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824644A (en) * 1994-07-07 1998-10-20 G. D. Searle & Co. Method of attenuating arterial stenosis
US5648331A (en) * 1994-08-26 1997-07-15 G.D. Searle & Co. Method of inhibiting tissue ischemia and reperfusion injury
US5914316A (en) * 1994-12-16 1999-06-22 Washington University Method of inhibiting intimal hyperplasia
WO1996040224A1 (en) * 1995-06-07 1996-12-19 Chiron Corporation Regulation of cytokine synthesis and release
US5772629A (en) * 1995-10-23 1998-06-30 Localmed, Inc. Localized intravascular delivery of TFPI for inhibition of restenosis in recanalized blood vessels
US5981471A (en) * 1997-02-06 1999-11-09 Entremed, Inc. Compositions and methods for inhibiting cellular proliferation
EP1980617A1 (de) 1998-12-31 2008-10-15 Novartis Vaccines and Diagnostics, Inc. Verbesserte Expression von HIV-Polypeptiden und Herstellung virusähnlicher Partikel
AU2002228911A1 (en) * 2000-11-08 2002-05-21 The General Hospital Corporation Methods for inhibiting pain
US6939716B2 (en) 2001-09-19 2005-09-06 Washington University Method for detecting conditions indicative of sepsis
IL161407A0 (en) 2001-10-15 2004-09-27 Chiron Corp Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (tfpi)
US7851433B2 (en) 2003-08-13 2010-12-14 Novartis Vaccines And Diagnostics, Inc. Method of purifying TFPI and TFPI analogs

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK408089D0 (da) * 1989-08-18 1989-08-18 Novo Nordisk As Proteiner

Also Published As

Publication number Publication date
JPH07507300A (ja) 1995-08-10
JP2007137901A (ja) 2007-06-07
JP3957740B2 (ja) 2007-08-15
PT643585E (pt) 2000-05-31
CA2136953A1 (en) 1993-12-09
CA2136953C (en) 2006-10-31
WO1993024143A1 (en) 1993-12-09
GR3032779T3 (en) 2000-06-30
DE69327314T2 (de) 2000-04-13
JP2004210801A (ja) 2004-07-29
ES2139658T3 (es) 2000-02-16
DK0643585T3 (da) 2000-05-08
DE69327314D1 (de) 2000-01-20
EP0643585A1 (de) 1995-03-22
EP0643585B1 (de) 1999-12-15

Similar Documents

Publication Publication Date Title
DE68919358D1 (de) Zusammensetzung zur behandlung der schizophrenie.
ATE140388T1 (de) Zusammensetzungen enthaltend omega conotoxin peptide derivate und deren verwendung zur behandlung von ischämie-artigen neuronalen schädigungen
DE69132688D1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
DE69218255D1 (de) Verwendung von amino-2-trifluormethoxy-6-benzothiazol (riluzol) zur herstellung eines medikamentes zur behandlung von erkrankungen des motoneurons
ATE157542T1 (de) Verwendung von einer disaccharidpolysulfat- aluminium verbindung zur herstellung eines medikaments zur behandlung von hämorrhoiden und zur wundheilung
DE69006684D1 (de) Verwendung einer Zusammensetzung zur Herstellung eines Arzneimittels zur Behandlung der Symptome der Unenthaltsamkeit.
ATE226433T1 (de) Verbesserte aminosaureloesungen zur behandlung bei peritonealer dialyse
DE69535264D1 (de) Verfahren zur behandlung von diabetes mittels kgf
AU5051693A (en) Method and composition for treating inflammatory bowel disorders
DE69327314D1 (de) Zusammensetzungen enthaltend Lipoprotein-Associated-Coagulation-Inhibitor (LACI) zur Herstellung eines Medikaments zur Behandlung von akuten oder chronischen Enzündungen
PT93935A (pt) Processo para a preparacao de uma composicao farmaceutica para o tratamento topico de acne vulgar contendo cetoconazol
ATE201597T1 (de) Verabreichung von riluzol zur behandlung von neuro-aids
ES2107470T3 (es) Producto que contiene factor de crecimiento y glutamina y uso del factor de crecimiento para el tratamiento de la mucosa intestinal.
ATE138567T1 (de) Zusammensetzung und verfahren zur behandlung von schmerzvollen entzündlichen oder allergischen erkrankungen
DE69328838D1 (de) Antipyretische und analgetische verfahren und zusammensetzungen, die optisch reines r-etodolac enthalten
DE59902666D1 (de) Edelfosin zur behandlung von hirntumoren
ATE169226T1 (de) Verwendung von aus blutplättchen gewonnenem wachstumsfaktor zur herstellung eines medikaments zur behandlung von gastrointestinaler geschwüre
DE69026511D1 (de) Verwendung von gibberellinen zur herstellung eines arzneimittels zur behandlung von prostatitis
ATE430578T1 (de) Faktor viii oder von willebrand faktor zur behandlung von thrombopathie assoziierenden hämorrhagischen erkrankungen
ATE249832T1 (de) Verwendung von olanzapin oder eines salzes für die herstellung eines medikaments für die behandlung von autismus und mentaler retardation
DE69307702D1 (de) Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit
ATE173921T1 (de) Verwendung von deoxyspergualin zur herstellung eines arzneimittels zur behandlung von entzündlich-hyperreaktiven erkrankungen
DE69004267D1 (de) Glycyl-p-amino-pyridin zur behandlung von seniler demenz.
RU97109107A (ru) Способ лечения гнойных ран
SU1113093A1 (ru) Способ лечени остеомиелита

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee